Ingenza Ltd. is a boutique, employee-owned CRDMO that develops smarter bioprocesses across life sciences and industrial biotech. With over two decades of experience, Ingenza combines molecular biology, biocatalysis, and computational design into a platform-based approach that enables predictable, scalable, and efficient biomanufacturing. At the heart of our offering are proprietary inGenius platform that drive decision-making and accelerate development: codABLE™ – our machine learning-driven gene optimization tool for intelligent codon selection and expression tuning Rapid Strain and Cell Line Development – modular workflows for host selection, expression screening, and stability assessment Integrated Process Development – upstream and downstream optimization with in-line analytics and scale-up readiness Our platform-based model allows us to tailor solutions while minimizing development risk and cost. Whether developing a production cell line for complex biologics or engineering a novel biocatalyst, our tools and expertise ensure results are reproducible, transferrable, and ready for scale. Core capabilities include: • Gene-to-protein expression in microbial and mammalian systems • High-throughput construct and strain screening • Cell line development and fermentation scale-up • Protein purification and analytical method development • Biocatalyst engineering and synthetic pathway design • Custom scale material manufacture As a boutique CRDMO, we combine scientific depth with personalized attention — offering the flexibility, responsiveness, and focus that larger providers often can’t. Our customers benefit from close collaboration, transparent communication, and solutions tailored to their unique challenges.
Looking for a particular Ingenza Ltd employee's phone or email?
The Ingenza Ltd annual revenue was $5 million in 2026.
Nick Challoner is the CEO of Ingenza Ltd.
37 people are employed at Ingenza Ltd.
The NAICS codes for Ingenza Ltd are [54, 541, 5417, 54171, 541713].
The SIC codes for Ingenza Ltd are [87, 873].